PRINCETON, N.J.– ArrePath, Inc., an emerging biotechnology company focused on applying deep phenotypic insights and machine learning to the discovery of new anti-infectives, today announced the appointment of Kevin Krause as President and Chief Executive Officer. Mr. Krause brings more than 25 years of experience in research, clinical development, commercialization, and corporate development in the biotech industry, as the company continues to expand its pipeline of internally discovered assets.
Mr. Krause most recently served as the Chief Strategy Officer of AN2 Therapeutics, Inc., a company applying boron chemistry to the discovery and development of novel therapies. In this role, he was the Project Team leader for AN2’s epetraborole Phase 2/3 NTM lung disease program, while overseeing various departments including Project Management, Clinical Operations, Regulatory, Quality, Medical Writing, and Corporate Development. Earlier in his career, he held various positions in R&D leadership and Corporate Business Development at Achaogen, Cerexa, and Theravance BioPharma, where he was instrumental in the clinical development and/or approval of Zemdri® (plazomicin), Avycaz® (ceftazidime-avibactam), Vibativ® (telavancin), Teflaro® (ceftaroline fosamil), Colobreathe® (inhaled colistin) and Quinsair® (inhaled levofloxacin).
Mr. Krause received an M.B.A. from the University of California, Berkeley Haas School of Business and a B.S. in Cell and Molecular Biology from San Francisco State University.
“We are thrilled to welcome Kevin as the new Chief Executive Officer of ArrePath,” said co-founder Dr. Zemer Gitai, on behalf of the company’s Board of Directors. “Thanks to his exceptional track record of visionary leadership, we are confident that Kevin will use the team’s momentum to advance their lead program to the clinic and unlock new opportunities for growth. This is an exciting new chapter for ArrePath and we look forward to the positive impact Kevin will bring to the company and its stakeholders.”
“I am honored to join ArrePath, which has made tremendous progress on the application of its proprietary AI/ML platform to discover antibacterials with novel mechanisms of action,” said Mr. Krause. “I look forward to working with the team to advance our lead program and to expand our existing portfolio.”
